Lundbeck Sees $179 Million in Sales for New Drug, Berlingske Say

H. Lundbeck A/S expects its experimental epilepsy treatment clobazam, if approved, will generate annual sales of more than billion kroner ($179 million), Berlingske Tidende reported, citing spokesman Mads Kronborg.

Lundbeck released trial results over the weekend which showed the two highest doses of the medicine, when added on to existing therapy, cut the number of seizures that patients experienced by a statistically significant amount.

Click here for web link

To contact the editor responsible for this story: Frances Schwartzkopff at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.